Is NeuroSense Therapeutics Ltd. (NRSN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.3% / 30% | 11.7% / 30% | 0.6% / 30% | N/A | ✓ HALAL |
| DJIM | 0.3% / 33% | 11.7% / 33% | 0.6% / 33% | N/A | ✓ HALAL |
| MSCI | 1.6% / 33% | 73.8% / 33% | 3.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.3% / 33% | 11.7% / 33% | 0.6% / 33% | N/A | ✓ HALAL |
| FTSE | 1.6% / 33% | 73.8% / 33% | 3.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -303.9% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$10M |
| Free Cash Flow | -$10M |
| Total Debt | $73,000 |
| Current Ratio | 0.7 |
| Total Assets | $5M |
Price & Trading
| Last Close | $0.77 |
| 50-Day MA | $0.89 |
| 200-Day MA | $1.22 |
| Avg Volume | 220K |
| Beta | 1.6 |
|
52-Week Range
$0.63
| |
About NeuroSense Therapeutics Ltd. (NRSN)
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is NeuroSense Therapeutics Ltd. (NRSN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), NeuroSense Therapeutics Ltd. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is NeuroSense Therapeutics Ltd.'s debt ratio?
NeuroSense Therapeutics Ltd.'s debt ratio is 0.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.6%.
What are NeuroSense Therapeutics Ltd.'s key financial metrics?
NeuroSense Therapeutics Ltd. has a market capitalization of $24M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.